ArticleInternational archives of allergy and immunology2014
A ten-year retrospective analysis of the distribution, use and phenotypic characteristics of the LAD2 human mast cell line.
Article in International archives of allergy and immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current utilization trend of immortalized mast cell lines in allergy research: a systematic review.Immunologic research · 2025Pooled it
- Ticked Off: Allergic Effector Cells in the Pathogenesis of Alpha-gal Syndrome.Current allergy and asthma reports · 2025Review
- Evolution of mast cell research associated with the Laboratory of Allergic Diseases, 1985-2022: Summary of the 2023 NIAID Symposium.The Journal of allergy and clinical immunology · 2025Review
- A hand-operated microfluidic sample preparation-to-analysis workflow for simplifying the basophil activation test.Lab on a chip · 2025Article
- Clinical utility analysis of the Hoxb8 mast cell activation test for the diagnosis of peanut allergy.Allergy · 2025Article
- Inducible pluripotent stem cells to study human mast cell trajectories.Mucosal immunology · 2024Article
- Article
- Degranulation of human mast cells: modulation by P2 receptors' agonists.Frontiers in immunology · 2023Review
- Where's the Beef? Understanding Allergic Responses to Red Meat in Alpha-Gal Syndrome.Journal of immunology (Baltimore, Md. : 1950) · 2022Review
- Mast Cell-Biomaterial Interactions and Tissue Repair.Tissue engineering. Part B, Reviews · 2021Review
- Dermal Extracellular Matrix-Derived Hydrogels as anTissue engineering. Part A · 2021Article
- Aurora kinase inhibitor tozasertib suppresses mast cell activation in vitro and in vivo.British journal of pharmacology · 2020Article
- Microfluidic methods for precision diagnostics in food allergy.Biomicrofluidics · 2020Review
- Mast Cell and Basophil Cell Lines: A Compendium.Methods in molecular biology (Clifton, N.J.) · 2020Review
- Mast Cell Activation Test (MAT).Methods in molecular biology (Clifton, N.J.) · 2020Article
- Mast cell activation test in the diagnosis of allergic disease and anaphylaxis.The Journal of allergy and clinical immunology · 2018Article
- Years in Review: Recent Progress in Cellular Allergology.International archives of allergy and immunology · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIn 2003, this laboratory published an account of the human mast cell line LAD2 (Laboratory of Allergic Diseases 2) that expressed FcεRI, responded to recombinant human stem cell factor (rhSCF) and resembled CD34+-derived human mast cells. LAD2 cells have now been distributed worldwide. To study the impact of this transfer, we analyzed the number of investigators receiving LAD2 cells and resulting publications.
methodsRecords maintained in our laboratory, the Technology Transfer and Intellectual Property Office and Office of Technology Transfer, were reviewed for material transfer agreements (MTAs) and licensing agreements (LAs). Journals and impact factors were obtained from PubMed.gov by cross-referencing LAD2 and human mast cells from 2003 through November 2013.
resultsOver 300 MTAs and 40 LAs were approved. LAD2 cells were shipped to over 30 countries. More than 80 papers have been published in journals with impact factors from 1.31 to 13.21. Intended uses include the study of receptors, degranulation, and cell signaling. LAD2 cells continue to express described markers and have consistent FcεR1-mediated degranulation.
conclusionsSuccess of the LAD2 line reflects the demand for a human mast cell line in research, the uniqueness of this cell line, and that it continues to exhibit minimal variation from its original description. We hope that the awareness of the impact of this cell line on mast cell research will encourage others to develop and distribute other similar cell lines with additional characteristics so as to address the limitations of depending on the study of cultured human mast cells from tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.